Id1-/- mice treated with the anti-PD-1 monoclonal antibody showed a significantly reduced tumor growth and longer survival in comparison to results seen in control groups (Id1-/-/DPBS p = 0.0283; Id1+/+/anti-PD-1 p = 0.0039; Id1+/+/DPBS p < 0.0001) (Figure 3A–C). This evidence concerns the gene ID1 and neoplasm.